Peginterferon lambda-1a(ZymoGenetics, Inc.)

The increasing occurrence of chronic and infectious diseases is the main driver of the rising demand for interferon. Furthermore, advancements in interferon production and ongoing research and development of innovative interferon therapies are key factors fueling the expansion of the interferon market from 2025 to 2032. LAS VEGAS, March 5, 2025 /PRNewswire/ -- DelveInsight's Interferons Market Insights report provides the current and forecast market analysis, individual leading interferons companies' market shares, challenges, interferons market drivers, barriers, trends, and key market interferons companies in the market. Key Takeaways from the Interferons Market Report As per DelveInsight estimates, North America is anticipated to dominate the global interferons market during the forecast period. In the application segment of the interferon market, the leukemia category captured a significant revenue share in 2024. Notable interferons companies such as Bayer AG, Amega Biotech, Biogen, Merck KGaA, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Biosidus, AOP Orphan Pharmaceuticals GmbH, Reliance Life Sciences, and several others, are currently operating in the interferons market. In September 2022, Eiger BioPharmaceuticals, a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, provided an update on the status of its planned request for emergency use authorization (EUA) of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19 based on its most recent communications with the U.S. Food and Drug Administration (FDA). To read more about the latest highlights related to the interferons market, get a snapshot of the key highlights entailed in the Global Interferons Market Report Interferons Overview Interferons (IFNs) are a group of signaling proteins that play a critical role in the immune response, particularly in defending against viral infections and modulating the activity of immune cells. They are classified into three main types: Type I (such as IFN-α and IFN-β), Type II (IFN-γ), and Type III (IFN-λ). Type I interferons are primarily produced in response to viral infections and function by activating antiviral pathways in host cells, inhibiting viral replication, and enhancing the activity of natural killer (NK) cells. IFN-γ, the sole Type II interferon, is crucial for activating macrophages and promoting adaptive immune responses, particularly in bacterial and tumor immunity. Type III interferons share functional similarities with Type I IFNs but act more selectively on epithelial cells, making them important in mucosal immunity. Beyond their antiviral properties, interferons have significant roles in cancer immunotherapy and autoimmune diseases. They enhance antigen presentation, stimulate cytotoxic T cells, and modulate the tumor microenvironment, contributing to immune surveillance against malignancies. Clinically, recombinant interferons have been used to treat conditions such as hepatitis B and C, multiple sclerosis, and certain cancers. However, prolonged interferon therapy can lead to adverse effects, including flu-like symptoms, fatigue, and autoimmune complications. Recent research is focused on optimizing interferon-based therapies and combining them with immune checkpoint inhibitors or other immunomodulators to improve efficacy while minimizing toxicity. Interferons Market Insights North America holds the largest interferons market share due to a strong presence of biopharmaceutical companies, robust R&D investments, and high healthcare expenditure. The U.S. market, in particular, benefits from a well-established regulatory framework and widespread adoption of advanced biotherapeutics. Meanwhile, Europe follows closely, with key contributions from Germany, France, and the UK, where government support for biotech innovation and access to novel biologics drive market expansion. In the Asia-Pacific region, the interferon market is witnessing rapid growth, fueled by rising healthcare infrastructure, an increasing prevalence of infectious diseases, and government initiatives to boost biopharmaceutical production. China and India are emerging as major players, with domestic companies investing heavily in biosimilar development and expanding manufacturing capacities. Latin America and the Middle East & Africa are also showing potential, albeit at a slower pace, due to improving healthcare access and growing awareness of biologic treatments. However, market expansion in these regions is challenged by high drug costs and regulatory hurdles, which may impact the adoption of interferon therapies. To know more about why North America is leading the market growth in the interferons market, get a snapshot of the Interferons Market Outlook Interferons Market Dynamics The interferons market is driven by their critical role in treating viral infections, autoimmune diseases, and various cancers. Interferons (IFNs) are a class of cytokines that modulate the immune response, making them valuable in antiviral therapies (such as hepatitis B and C), multiple sclerosis, and oncology applications. The increasing prevalence of these diseases, along with rising research into novel interferon-based therapies, continues to fuel market growth. However, the market faces challenges due to the emergence of alternative therapies, such as monoclonal antibodies and small-molecule inhibitors, which offer higher efficacy and fewer side effects. One of the key factors influencing market dynamics is the shift from traditional interferon therapies to newer, more targeted treatments. For instance, in the treatment of hepatitis C, direct-acting antiviral agents (DAAs) have largely replaced interferon-based regimens due to their superior cure rates and reduced adverse effects. Similarly, in multiple sclerosis, oral therapies and monoclonal antibodies such as ocrelizumab and natalizumab have overshadowed interferon-beta treatments. Despite this, interferons remain relevant in certain applications, such as rare cancers and specific immune disorders where alternative treatments are not as effective. Another factor shaping the interferons market is the regulatory landscape. Interferons are biologic drugs, meaning they are subject to stringent approval processes and high production costs. The development of biosimilar interferons has the potential to make these therapies more accessible, especially in emerging markets. However, biosimilars face challenges in gaining market traction due to concerns about immunogenicity and physician preference for established brands. Companies investing in next-generation interferons with improved efficacy and safety profiles may have an opportunity to capture a share of this evolving market. Looking ahead, the future of the interferons market will be shaped by ongoing innovation, competitive pressures, and the need for cost-effective biologics. While traditional interferon therapies may continue to decline in some areas, their role in niche indications and combination therapies could sustain market demand. Companies focusing on improving delivery methods, reducing side effects, and exploring novel interferon applications in immuno-oncology and rare diseases may unlock new growth opportunities in this evolving landscape. Get a sneak peek at the interferons market dynamics @ Interferons Market Dynamics Analysis Interferons Market Assessment Interferons Market Segmentation Interferons Market Segmentation By Type: Alpha, Beta, and Gamma Interferons Market Segmentation By Application: Hepatitis B, Hepatitis C, Leukemia, Multiple Sclerosis, and Others Interferons Market Segmentation By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others Interferons Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the interferons market are set to emerge as the trendsetter explore @ Interferons Companies Table of Contents Interested in knowing the interferons market by 2032? Click to get a snapshot of the Interferons Market Trends Related Reports Multiple Sclerosis Market Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple sclerosis companies, including Immune Response BioPharma, Inc., Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Inc., Apimeds Inc., Bayer HealthCare, Novartis, Biogen, Alkermes, Genentech, among others. Multiple Sclerosis Pipeline Multiple Sclerosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple sclerosis companies, including Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse, among others. Chronic Hepatitis B Market Chronic Hepatitis B Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic hepatitis B companies, including GlaxoSmithKline, Ionis Pharma, Beijing Continent Pharmaceutical, Ascletis Pharmaceuticals, Vir Biotechnology, Brii Biosciences, Janssen, Arrowhead Pharmaceuticals, among others. Chronic Hepatitis B Pipeline Chronic Hepatitis B Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic hepatitis B companies, including Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

iStock, Yutthana Gaetgeaw 2023 marked the most bankruptcies in biopharma in more than a decade, with 14 companies filing for Chapter 11 protection. The number remained high in 2024. Biopharma bankruptcies are still at higher-than-normal levels, with 2024 seeing 13 firms go under in this way—just one less than the industry’s 10-year high of 14 in 2023—underscoring the perilous fundraising situation that has persisted since the pandemic bubble burst. “Chapter 11 is really just the tip of the iceberg,” Cristine Schwarzman, a partner in Ropes & Gray’s business restructuring practice, told BioSpace in an email. While the bankruptcy code is the most commonly reported way that companies shut down, it’s not the only way. “Many more biotechs go through ABC proceedings and just dissolve, because those processes are less expensive and quicker, even though they do not provide the same benefits as the ‘free and clear’ provisions of the bankruptcy code,” Schwarzman said. Prior to 2023, the highest number of biopharma bankruptcies since 2010 came in 2019 when seven companies filed for Chapter 11 protection. David McIntosh, also a partner at Ropes & Gray in the life sciences and intellectual property transactions practice, said the key driver of this recent peak is fundraising challenges, particularly as interest rates have risen and strained access to capital. There has also been economic uncertainty due to the political environment, leading to more restrained investing, McIntosh explained. “The public markets have been cool for biotech companies, and private investors, like VCs, are being more selective in which (and how many) companies they are willing to invest in,” he told BioSpace . in an email. Meanwhile, Big Pharma has not been as quick to deal as analysts and investors had hoped, and the larger companies have also cut back on R&D expenditures. This challenging funding environment follows the pandemic boom, which saw an influx of funds across the life sciences. “The ease with which companies were able to raise capital during the pandemic resulted in biotech companies taking on more debt financing than previously in the life sciences industry,” Schwarzman said. Because of the high rate of debt financings, more companies had to go through the bankruptcy process to “de-lever” their balance sheets, she added. “I think it is also safe to say that during the pandemic, a number of private biotech companies went public that might not have been able to in normal market times,” McIntosh said. These public companies are more likely to seek bankruptcy protection because they typically have a higher valuation, more complex capital structure and investors with access to capital to fund the Chapter 11 process, Schwarzman said. Smaller private companies, on the other hand, tend to be able to wrap things up through state court processes. “To be clear, however, both private and public biotech companies are facing financial pressure right now,” Schwarzman added. Unfortunately, Schwarzman and McIntosh see the trend continuing this year. Due to geopolitical uncertainty “and the increasing likelihood that interest rates will at a minimum not be cut to deal with the continuing inflationary environment,” McIntosh said, “we do not expect these trends to fall off.” Beginning of the End To McIntosh, the most surprising bankruptcy of 2024 was Eiger BioPharmaceuticals, a metabolic disease biotech that was advancing peginterferon lambda for chronic hepatitis delta until a liver safety signal arose in a Phase III trial. “It had raised a lot of money and had a lot of interesting assets, but experienced a Phase III failure in 2023, which seemed to be the beginning of the end,” McIntosh said. Eiger sold off its assets, with some landing at Amylyx Pharmaceuticals for future development. Amylyx paid $35 million for the glucagon-like peptide-1 receptor antagonist avexitide, which is expected to begin a Phase III trial this quarter . This is a fairly typical path for the assets left behind in a biotech bankruptcy, McIntosh explained. The intellectual property is sold to other companies, presenting the new owner with the opportunity to use the assets to attract new financing at a lower valuation, he said; it also gives the drugs a second chance. Another major bankruptcy of 2024 was Gritstone bio, which filed in October in an effort to save its R&D operations. The vaccines-focused biotech was pursuing a stalking horse transaction, when a party swoops in to buy out a bankrupt company’s assets prior to a court auction process. Ultimately, Gritstone’s assets were auctioned off for $21.2 million, according to a Jan. 3 filing. Gritstone was optimistic about Phase II results for its Granite program in September 2024, which showed a 21% relative risk reduction of progression or death in patients taking the study medication versus standard of care. But the data needed more time to mature and Gritstone was running out of runway, with just $61.7 million on hand, leading to the bankruptcy filing. Cell therapy biotech Athersys was another company to file, going the stalking horse route and selling its assets to Healios for around $2 million in January 2024. Athersys had been developing its MultiStem off-the-shelf cell therapy since 1994 in ischemic stroke in partnership with Healios. Other indications included traumatic injury and acute respiratory distress syndrome. A Phase III trial in stroke that read out in October 2023 was unsuccessful . This year, the bankruptcies have already started. According to a Jan. 29 SEC filing , Flagship Pioneering spinout Omega Therapeutics had until Feb. 10 to commence bankruptcy proceedings and begin to wind down operations, likely involving a sale process with Pioneering Medicines, an affiliate of Flagship Pioneering. The news came just over a year after Omega struck an obesity deal with Novo Nordisk. “As long as the public markets disfavor biotech companies, and private investors shy away from ‘riskier’ early-stage investments,” McIntosh said, “the trend will continue.” A note about the data: BioSpace ’s last bankruptcy analysis clocked 28 bankruptcies for 2023 as of October of that year. Our new analysis uses narrower criteria, including only companies making therapeutics. Our source for bankruptcies also shifted to S&P Capital IQ and company SEC filings.